Lunxu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lunxu Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Guowei Che
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
3 shared publications - Cheng Shen
Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China.
2 shared publications - Cheng Shen
Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China
1 shared publication - Dali Chen
Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China.
1 shared publication - Heng Du
Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China.
1 shared publication - Huan Xu
Department of Pathology, West-China Hospital, Sichuan University, Chengdu, 610041, China
1 shared publication
Latest Publications
- Open Access
- 15 July 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis
Lung cancer is the most important cause of cancer-related deaths worldwide and the overall survival of patients with non-small cell lung cancer has not improved. Transforming growth factor beta or TGF-β is a polypeptide member of the transforming growth factor beta superfamily of cytokines, while far fewer clinical studies addressing the association between TGF-β expression and the disease prognosis have been reported up to now. Therefore, our meta-analysis aims to determine the prognostic significance of TGF-β expression in lung cancer patients. PubMed, EMBASE, the Web of Science and China National Knowledge Infrastructure (CNKI) databases were searched for full-text literature citations. We applied the hazard ratio (HR) with 95% confidence interval (CI) as the appropriate summarized statistics. Q-test and I2 statistic were used to estimate the level of heterogeneity. The publication bias was detected by Begg’s test and Egger’s test. Eight eligible studies involving 579 patients were selected for this meta-analysis. The combined HR for the eight eligible studies was 2.17 (95% CI: 1.71–2.77, P < 0.00001) and heterogeneity of overall prognosis was relatively low (I2 = 14.2%, P = 0.319). We further undertook the subgroup analysis including assessment of the association between TGF-β expression and pathology of the lung cancer, treatment and quantity of sample in studies. All the results revealed that a significantly high TGF-β expression in patients was an indicator of poor survival. Neither Begg’s test nor Egger’s test found publication bias in any analysis. The present evidence indicates that TGF-β expression can significantly predict the worse prognosis in patients with lung cancer. The findings of our meta-analysis may be confirmed in the future by the use of more updated review pooling and additional relevant investigations.
- 15 July 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Open AccessPrognostic value of TGF-β in lung cancer: systematic review and meta-analysis
Lung cancer is the most important cause of cancer-related deaths worldwide and the overall survival of patients with non-small cell lung cancer has not improved. Transforming growth factor beta or TGF-β is a polypeptide member of the transforming growth factor beta superfamily of cytokines, while far fewer clinical studies addressing the association between TGF-β expression and the disease prognosis have been reported up to now. Therefore, our meta-analysis aims to determine the prognostic significance of TGF-β expression in lung cancer patients. PubMed, EMBASE, the Web of Science and China National Knowledge Infrastructure (CNKI) databases were searched for full-text literature citations. We applied the hazard ratio (HR) with 95% confidence interval (CI) as the appropriate summarized statistics. Q-test and I2 statistic were used to estimate the level of heterogeneity. The publication bias was detected by Begg’s test and Egger’s test. Eight eligible studies involving 579 patients were selected for this meta-analysis. The combined HR for the eight eligible studies was 2.17 (95% CI: 1.71–2.77, P < 0.00001) and heterogeneity of overall prognosis was relatively low (I2 = 14.2%, P = 0.319). We further undertook the subgroup analysis including assessment of the association between TGF-β expression and pathology of the lung cancer, treatment and quantity of sample in studies. All the results revealed that a significantly high TGF-β expression in patients was an indicator of poor survival. Neither Begg’s test nor Egger’s test found publication bias in any analysis. The present evidence indicates that TGF-β expression can significantly predict the worse prognosis in patients with lung cancer. The findings of our meta-analysis may be confirmed in the future by the use of more updated review pooling and additional relevant investigations.
- Open Access
- 20 February 2015
- Published by Springer Nature in European Journal of Medical Research
- Vol. 20 (1) , 17
“Different trend” in multiple primary lung cancer and intrapulmonary metastasis
The distinguishing of intrapulmonary metastatic tumors from multiple primary lung cancers is difficult but of great importance for the therapeutic management and prognosis of these patients. We used genomic DNA analyzed by six microsatellites (D7S1824, D15S822, D2S1363, D10S1239, D6S1056, and D22S689) with PCR to identify discordant allelic variation from 12 patients. There are five patients with multiple primary lung cancers and seven patients who were diagnosed with intrapulmonary metastases from 850 patients with primary lung cancer in our hospital. The experiments were approved by the West China Hospital Ethics committee (No. 2013 (33)) and all patients agreed to participate in the study and signed an informed consent form. In the group of metachronous lung tumor, three of five patients have different histological types and one of five patients have the same histological type which showed “contradictory trend”. The other one showed “unique trend”. In the second group (intrapulmonary metastasis lung tumor), one patient showed “contradictory trend” and the others showed “unique trend”. “Different trends” are useful in discrimination of intrapulmonary metastasis lung cancer and multiple primary lung cancer even diagnosed with the histopathological evaluation.
- 20 February 2015
- Published by Springer Nature in European Journal of Medical Research
- Vol. 20 (1) , 17
Open Access“Different trend” in multiple primary lung cancer and intrapulmonary metastasis
The distinguishing of intrapulmonary metastatic tumors from multiple primary lung cancers is difficult but of great importance for the therapeutic management and prognosis of these patients. We used genomic DNA analyzed by six microsatellites (D7S1824, D15S822, D2S1363, D10S1239, D6S1056, and D22S689) with PCR to identify discordant allelic variation from 12 patients. There are five patients with multiple primary lung cancers and seven patients who were diagnosed with intrapulmonary metastases from 850 patients with primary lung cancer in our hospital. The experiments were approved by the West China Hospital Ethics committee (No. 2013 (33)) and all patients agreed to participate in the study and signed an informed consent form. In the group of metachronous lung tumor, three of five patients have different histological types and one of five patients have the same histological type which showed “contradictory trend”. The other one showed “unique trend”. In the second group (intrapulmonary metastasis lung tumor), one patient showed “contradictory trend” and the others showed “unique trend”. “Different trends” are useful in discrimination of intrapulmonary metastasis lung cancer and multiple primary lung cancer even diagnosed with the histopathological evaluation.
- Open Access
- 25 October 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 323
Cavernous hemangioma of thymus misdiagnosed as thymoma: a case report
Cavernous hemangioma in the thymus is a rare presentation in mediastinal hemangiomas. The diagnosis is difficult to make promptly because both invasive and noninvasive examinations usually fail to distinguish it from other tumors of the mediastinum. Their clinical presentations depends on their size and their involvement with adjacent mediastinal structures. We treated a 52-year-old man with thymic cavernous hemangioma that was incidentally detected by chest radiography during a routine health check, and had been misdiagnosed as thymoma before the operation. The tumor was completely resected by thymectomy via video-assisted thoracic surgery. The pathological tissue was diagnosed as a cavernous hemangioma, and no phlebolith was observed in the center. We reported this case of thymic cavernous hemangioma for its extremely rare occurrence in the thymus. The preoperative diagnosis remains a challenge both clinically and radiologically. It is still difficult to distinguish this tumor from other tumors in the thymus. Furthermore, biopsies might not result in a definitive diagnosis. Finally, surgical resection provides material for histopathologic diagnosis. To facilitate the preoperative diagnosis of such a rare tumor, more cases will need to be reported.
- 25 October 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 323
Open AccessCavernous hemangioma of thymus misdiagnosed as thymoma: a case report
Cavernous hemangioma in the thymus is a rare presentation in mediastinal hemangiomas. The diagnosis is difficult to make promptly because both invasive and noninvasive examinations usually fail to distinguish it from other tumors of the mediastinum. Their clinical presentations depends on their size and their involvement with adjacent mediastinal structures. We treated a 52-year-old man with thymic cavernous hemangioma that was incidentally detected by chest radiography during a routine health check, and had been misdiagnosed as thymoma before the operation. The tumor was completely resected by thymectomy via video-assisted thoracic surgery. The pathological tissue was diagnosed as a cavernous hemangioma, and no phlebolith was observed in the center. We reported this case of thymic cavernous hemangioma for its extremely rare occurrence in the thymus. The preoperative diagnosis remains a challenge both clinically and radiologically. It is still difficult to distinguish this tumor from other tumors in the thymus. Furthermore, biopsies might not result in a definitive diagnosis. Finally, surgical resection provides material for histopathologic diagnosis. To facilitate the preoperative diagnosis of such a rare tumor, more cases will need to be reported.